Keros Therapeutics, Inc. KROS
11.62
0.07
0.61%
as of 25 Sep
- Market cap
- $229.0M
- P/E
- 0.0×
Follow KROS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 10.95 |
P/S ratio |
— | 4.99 | 4.99 | — | 54.39 | — | 62.72 | 166.94 | 3.11 |
P/FCF ratio |
— | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 7.15 |
P/Operating CF |
— | (6.14) | (6.14) | — | (69.78) | — | (49.89) | (12.88) | (27.77) |
P/B ratio |
— | 0.00 | 0.00 | — | 5.61 | — | 3.82 | 1.04 | 2.50 |
Price to Tangible BV |
— | 0.00 | 0.00 | — | 5.61 | — | 3.82 | 1.04 | 2.50 |
EV/Sales |
— | (0.46) | (0.46) | — | 45.23 | — | 46.36 | 9.21 | 1.93 |
EV/EBITDA |
— | 0.26 | 0.26 | — | 0.00 | — | 0.00 | 0.00 | 6.81 |
EV/Operating CF |
— | 0.21 | 0.21 | — | (18.27) | — | (7.54) | (0.20) | 4.38 |
EV/FCF |
— | 0.21 | 0.21 | — | (17.97) | — | (7.39) | (0.20) | 4.44 |
Quick Ratio |
— | 2.03 | 1.77 | 37.04 | 20.94 | 16.91 | 13.59 | 20.50 | 14.36 |
Current Ratio |
— | 2.23 | 1.99 | 37.27 | 21.23 | 17.27 | 14.25 | 21.45 | 15.45 |
Net Debt/EBITDA |
— | 0.10 | 0.68 | 5.73 | 4.11 | 2.45 | 1.96 | 2.67 | (4.16) |
Debt/Assets |
0.00% | 84.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (3.22) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.73 | 0.52 | 0.00 | 0.08 | 0.00 | 0.00 | 0.01 | 0.51 |
Operating CF/Net income |
— | (3.00) | 1.13 | 0.81 | 1.06 | 0.67 | 0.81 | 0.86 | 1.24 |
Capex/Depreciation |
— | 0.00 | (1.30) | (1.06) | (2.71) | (1.84) | (3.02) | (1.57) | (1.03) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 17.62% | 106.17% | (37.45%) | (23.27%) | (40.21%) | (50.19%) | (41.46%) | 19.90% | |
| — | (17.12%) | (73.69%) | (32.35%) | (22.39%) | (37.25%) | (45.21%) | (38.01%) | 18.24% | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (268.30%) | 0.00% | (9,963.71%) | (1,133.80%) | 268.69% |
Return on Tangible Assets |
— | (15.19%) | (274.54%) | (17.36%) | (24.38%) | (38.59%) | (46.78%) | (33.12%) | 29.07% |
Average Days of Receivables |
— | 0.00 | 33.65 | 0.00 | 326.87 | 0.00 | 345.66 | 281.92 | 8.70 |
Research and Development Expense of Revenue |
— | 101.11% | 173.79% | 0.00% | 274.34% | 0.00% | 89,574.83% | 4,890.96% | 53.12% |
Selling, General and Administrative Expense of Revenue |
— | 12.76% | 31.84% | 0.00% | 106.12% | 0.00% | 23,068.87% | 1,148.00% | 19.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.59% | 0.00% | 58.32% | 0.00% | 19,048.34% | 982.31% | 11.76% |
Graham Net Nets |
— | 0.98 | 0.98 | — | 0.18 | — | 0.24 | 0.92 | 0.37 |
Graham Number |
— | 0.00 | 31.57 | — | 0.00 | — | 0.00 | 0.00 | 18.46 |
Earnings Yield |
— | (44.83%) | (44.83%) | — | (4.31%) | — | (12.06%) | (31.65%) | 9.14% |
Free Cash Flow Yield |
— | (44.21%) | (44.21%) | — | (4.63%) | — | (10.00%) | (27.47%) | 13.98% |
Revenue per Share |
— | 0.53 | 4.30 | 0.00 | 0.86 | 0.00 | 0.01 | 0.09 | 6.56 |
Operating CF per Share |
— | 0.37 | (6.87) | (2.38) | (2.66) | (2.78) | (4.23) | (4.30) | 2.89 |
Capex per Share |
— | 0.00 | (0.12) | (0.02) | (0.04) | (0.05) | (0.08) | (0.05) | (0.04) |
Free Cash Flow per Share |
— | 0.37 | (6.99) | (2.40) | (2.71) | (2.82) | (4.31) | (4.35) | 2.85 |
Cash per Share |
— | 1.23 | 3.02 | 17.15 | 9.86 | 11.06 | 11.25 | 14.96 | 7.72 |
Shareholders Equity per Share |
— | (0.38) | 0.21 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 | 8.14 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.38) | 0.21 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 | 8.14 |
Free Cash Flow |
— | 7.04 | (16.27) | (37.19) | (63.17) | (71.30) | (126.97) | (162.80) | 105.95 |
Working Capital |
— | 14.06 | 4.44 | 260.54 | 239.59 | 269.22 | 322.92 | 561.44 | 295.02 |
Capital Expenditures |
— | (0.22) | (0.27) | (0.29) | (1.02) | (1.24) | (2.46) | (1.93) | (1.55) |
Net Current Asset Value |
— | (9.06) | (1.53) | 260.00 | 239.36 | 256.41 | 309.48 | 544.56 | 280.55 |
EV/EBIT |
— | 0.25 | 0.25 | — | 0.00 | — | 0.00 | 0.00 | 6.96 |
Capex to Sales |
— | 0.00 | 0.03 | 0.00 | 0.05 | 0.00 | 16.32 | 0.54 | 0.01 |
Net Profit Margin |
— | (23.46%) | (141.36%) | 0.00% | (292.26%) | 0.00% | (101,319.21%) | (5,277.55%) | 35.65% |
Price to Operating Income |
— | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 11.22 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.22 | 0.29 | 0.38 | 0.28 | 0.33 | 0.20 | 0.29 | 0.35 |
Cash ROIC |
— | 14.44% | (222.30%) | (7.13%) | (13.42%) | (12.95%) | (19.39%) | (14.59%) | 17.48% |
Accounts Receivable Turnover |
— | 0.00 | 17.57 | 0.00 | 2.21 | 0.00 | 0.31 | 2.46 | 57.03 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 0.57 | 0.57 | 9.11 | 9.42 | 0.49 | 1.44 | 4.28 |
Average Payables |
— | 1.29 | 1.29 | 2.12 | 2.90 | 3.49 | 4.39 | 5.03 | 3.28 |
Average Assets |
— | 13.71 | 19.18 | 140.20 | 262.35 | 281.02 | 338.40 | 492.96 | 476.95 |
Average Common Equity |
— | (13.31) | (13.31) | 121.14 | 252.45 | 260.30 | 304.82 | 451.88 | 437.34 |
Columns are period end dates